Thyroid dermopathy and acropachy

Fatourechi, Vahab

doi:10.1016/j.beem.2011.10.001

Cited by 96 publications

(38 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thyroid dermopathy and acropachy Dermopathy, an uncommon immuno-inflammatory non-pitting symmetrical thickening of the skin in the pretibial area, appears similar to Graves' orbitopathy as far as etiopathogeny is concerned [90,91]. The two lesions are usually associated although dermopathy develops later.…”

Section: Extrathyroidal Manifestations Of Graves' Disease Orbitopathymentioning

confidence: 99%

See 1 more Smart Citation

Thyroid autoimmunity

Orgiazzi

2012

La Presse Médicale

View full text Add to dashboard Cite

Section: Extrathyroidal Manifestations Of Graves' Disease Orbitopathymentioning

confidence: 99%

“…Rarely, it is associated with similar lesions affecting the hands, fingers and digits, with clubbing. In some cases, plain radiographs show a periosteal reaction in the area of skin involvement [90,91]. The usual treatment of thyroid dermopathy is topical corticosteroids.…”

Section: Extrathyroidal Manifestations Of Graves' Disease Orbitopathymentioning

confidence: 99%

Thyroid autoimmunity

Orgiazzi

2012

La Presse Médicale

View full text Add to dashboard Cite

“…Almost all patients have coexisting ophthalmopathy. 28 The lesions are characterised by slightly pigmented thickened skin, primarily involving the pretibial area. 29 …”

Section: Clinical Presentation and Complicationsmentioning

confidence: 99%

Hyperthyroidism

2016

View full text Add to dashboard Cite

Hyperthyroidism is characterised by increased thyroid hormone synthesis and secretion from the thyroid gland, whereas thyrotoxicosis refers to the clinical syndrome of excess circulating thyroid hormones, irrespective of the source. The most common cause of hyperthyroidism is Graves’ disease, followed by toxic nodular goitre. Other important causes of thyrotoxicosis include thyroiditis, iodine-induced and drug-induced thyroid dysfunction, and factitious ingestion of excess thyroid hormones. Treatment options for Graves’ disease include antithyroid drugs, radioactive iodine therapy, and surgery, whereas antithyroid drugs are not generally used long term in toxic nodular goitre, because of the high relapse rate of thyrotoxicosis after discontinuation. β blockers are used in symptomatic thyrotoxicosis, and might be the only treatment needed for thyrotoxicosis not caused by excessive production and release of the thyroid hormones. Thyroid storm and hyperthyroidism in pregnancy and during the post-partum period are special circumstances that need careful assessment and treatment.

show abstract

“…GD is characterized by three main specifically extrathyroidal manifestations: PTM, Graves’ ophthalmopathy (GO), and thyroid acropachy. 2 , 3 PTM also occurs in patients with primary hypothyroidism and Hashimoto’s thyroiditis (HT). Interestingly, PTM has been reported, but very rarely, in patients with no past or present thyroid dysfunction.…”

Section: Introductionmentioning

confidence: 99%

“… 23 , 24 External application of fluocinolone acetonide, clobetasol propionate, and triamcinolone cream could be helpful. 3 , 6 Intralesional multiple injections of a solution of dexamethasone, lidocaine, and saline are also reported to result in significant resolutions. 19 , 25 Although local corticosteroid therapy has a certain curative effect on treatment of PTM, the poor response rate, high recurrence rate, and its adverse reactions are still huge problems.…”

Section: Introductionmentioning

confidence: 99%

Treatment of pretibial myxedema with intralesional immunomodulating therapy

Ren

Deng

et al. 2017

TCRM

View full text Add to dashboard Cite

ObjectiveLocal immune regulation therapy has been one of the therapeutic methods used for the treatment of autoimmune thyroid disease in patients with pretibial myxedema (PTM). However, the poor response rate and high recurrence rate are still major problems. Whether a premixed corticosteroid, compound betamethasone, could enhance remission rate and decrease recurrence rate in patients with PTM was investigated in the present study.Subjects and methodsWe have performed a clinical utility observation of compound betamethasone with intralesional injections based on basic thyroid disease treatment in 32 PTM patients between January 2008 and August 2016. The patients were followed up for 2 years, and the clinical outcomes and side effects were calculated and analyzed.ResultsAll patients had a complete remission after different times of injection. A total of 21.7% patients had complete remission with one time of injection, 34.8% with two times of injection, 17.4% with three times of injection, 4.3% with four times of injection, and 4.3% with five times of injection. In all, 56.3% patients with a disease duration of <6 months had complete remission after a 1-month treatment, 37.5% patients with a disease duration between 6 months and 12 months had complete remission after a 2-month treatment, 3.1% patients with a disease duration of 2 years had complete remission after a 5-month treatment, and 3.1% with a disease duration of 5 years had complete remission after a 7-month treatment.ConclusionCompound betamethasone with multipoint intralesional injection is a feasible, effective, and secure novel strategy in the treatment of PTM.

show abstract

Thyroid dermopathy and acropachy

Cited by 96 publications

References 86 publications

Thyroid autoimmunity

Thyroid autoimmunity

Hyperthyroidism

Treatment of pretibial myxedema with intralesional immunomodulating therapy

Contact Info

Product

Resources

About